Key Insights
Individual investors hold a considerable ownership stake in Outlook Therapeutics, giving them significant influence over management and business strategy. A total of 6 investors collectively own 52% of the company, with insiders making recent purchases.
Shareholders of Outlook Therapeutics, Inc. (NASDAQ:OTLK) reveal that individual investors have the largest ownership at 31%, followed by private equity firms at 31%. The chart below illustrates the breakdown of ownership groups within the company.
Hedge funds control 6.9% of Outlook Therapeutics shares, with GMS Ventures & Investments holding the largest share at 25%. The top 6 shareholders collectively own more than half of the company’s shares, indicating a balance of interests between larger and smaller shareholders.
Analyst sentiments and insider ownership are also important factors to consider. Insiders collectively own $2.2m worth of the company, showing some alignment with shareholders. The general public holds a 31% stake, while private equity firms and private companies own 31% and 11% respectively.
Considering the various ownership groups is essential for understanding Outlook Therapeutics. Further analysis is recommended to fully evaluate the company’s performance and future prospects. Identifying warning signs and potential growth opportunities will help stakeholders make informed decisions.
Please note that figures in this article are based on data from the last twelve months. For personalized financial advice, it is advisable to consult with a professional financial advisor.